Scholarlink

<p>Alzheimer's disease (AD) is a neurodegenerative disease characterized by cognitive declination, neuronal loss, &amp; multifaceted pathological mechanisms. Despite extensive scientific research, no definitive cure exists, but recent advancements in clinical trials highlight promising therapeutic strategies targeting multiple pathways involved in AD progression. Early-phase trials (Phases I and II) focus primarily on amyloid-beta (Aβ) and tau pathologies, with monoclonal antibodies like Aducanumab, Lacanemab, and Remternetug targeting Aβ clearance, while tau-directed agents such as E2814 and Bepranemab aim to reduce neurofibrillary tangle formation. Additionally, some novel approaches addressing neuroinflammation, bioenergetic disturbances, neurotransmitter modulation, and synaptic plasticity are emerging. In Phase III, late-stage candidates like Aducanumab, Donanemab, and Lecanemab have advanced, with some receiving regulatory approval, though their long-term clinical efficacy remains under evaluation. Phase IV studies further assess the long-term safety &amp; effectiveness of approved treatments in real world populations. The evolving landscape of AD therapeutics underscores a paradigm shift towards combination therapies and personalized medicine, recognizing AD as a multifactorial disorder.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

From bench to bedside: Emerging therapeutics for alzheimer's disease in clinical trials

  • 期刊论文

  • 发表日期：

    2026年3月18日

查看全文
  • Mansi Verma,
  • Niraj Kumar Singh

摘要

Alzheimer's disease (AD) is a neurodegenerative disease characterized by cognitive declination, neuronal loss, & multifaceted pathological mechanisms. Despite extensive scientific research, no definitive cure exists, but recent advancements in clinical trials highlight promising therapeutic strategies targeting multiple pathways involved in AD progression. Early-phase trials (Phases I and II) focus primarily on amyloid-beta (Aβ) and tau pathologies, with monoclonal antibodies like Aducanumab, Lacanemab, and Remternetug targeting Aβ clearance, while tau-directed agents such as E2814 and Bepranemab aim to reduce neurofibrillary tangle formation. Additionally, some novel approaches addressing neuroinflammation, bioenergetic disturbances, neurotransmitter modulation, and synaptic plasticity are emerging. In Phase III, late-stage candidates like Aducanumab, Donanemab, and Lecanemab have advanced, with some receiving regulatory approval, though their long-term clinical efficacy remains under evaluation. Phase IV studies further assess the long-term safety & effectiveness of approved treatments in real world populations. The evolving landscape of AD therapeutics underscores a paradigm shift towards combination therapies and personalized medicine, recognizing AD as a multifactorial disorder.